AbbVie said it expects GAAP and adjusted non-GAAP earnings for Q1 2025 to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis. The company said this is an unfavorable impact of $0.13 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.

1. 01

   AbbVie said it expects GAAP and adjusted non-GAAP earnings for Q1 2025 to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis. The company said this is an unfavorable impact of $0.13 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share.

2. 02

   AbbVie said it does not forecast acquired IPR&D and milestones expense because the timing and occurrence of such expense are uncertain. It said its 2025 outlook excludes expense incurred after Q1. The company also said the impact of its licensing agreement with Gubra to develop GUBGUB014295, which closed after Q1, is not reflected in this outlook.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.